
The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
Keywords: بیماری مزمن انسدادی ریه; Roflumilast; Phosphodiesterase 4; COPD; Preclinical pharmacology; Oral therapy; Inflammation